CBD Rescheduling: FDA Calls For Public Comment

CBD Rescheduling: FDA Calls For Public Comment

The US Food and Drug Administration is seeking public comments as to whether changes ought to be recommended regarding the international classification of cannabis “CBD” as a controlled substance. People have until October 31, 2018 to submit their comments to the FDA for consideration.

The feds want specifically to hear about the substances’ “abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use.”

The comment period was prompted by a call from the World Health Organization (WHO) for input regarding drug laws and potentially updating international drug treaties that bar nations from legalizing certain drugs — treaties that were championed by the U.S. government during the heyday of the drug war. Uruguay and Canada have both taken steps to federally legalize cannabis but, so far, the international community has not taken significant action against them.

Early October, reports surfaced that the FDA had called for the complete descheduling of CBD, the non-psychoactive cannabinoid most commonly associated with pain relief and epilepsy medication but DEA pushback resulted in a Schedule 5 classification for only FDA-approved drugs.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *